This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Law, D.
Right arrow Articles by Denning, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Law, D.
Right arrow Articles by Denning, D. W.

 Previous Article  |  Next Article 

Antimicrob. Agents Chemother., Oct 1997, 2310-2311, Vol 41, No. 10
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp

D Law, CB Moore and DW Denning
Department of Microbiology, Hope Hospital, Salford, United Kingdom.

The in vitro activity of Schering 56592, a new azole drug, was compared with those of fluconazole and itraconazole against 103 isolates of Candida comprising 10 different species. Schering 56592 was more active than itraconazole and fluconazole, and it was active against many fluconazole-resistant isolates.


This article has been cited by other articles:

  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006). In Vitro Activities of Posaconazole, Fluconazole, Itraconazole, Voriconazole, and Amphotericin B against a Large Collection of Clinically Important Molds and Yeasts.. Antimicrob. Agents Chemother. 50: 2009-2015 [Abstract] [Full Text]  
  • Carrillo-Munoz, A.-J., Quindos, G., Ruesga, M., Alonso, R., del Valle, O., Hernandez-Molina, J. M., McNicholas, P., Loebenberg, D., Santos, P. (2005). Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections. J Antimicrob Chemother 55: 317-319 [Abstract] [Full Text]  
  • Petraitiene, R., Petraitis, V., Groll, A. H., Sein, T., Piscitelli, S., Candelario, M., Field-Ridley, A., Avila, N., Bacher, J., Walsh, T. J. (2001). Antifungal Activity and Pharmacokinetics of Posaconazole (SCH 56592) in Treatment and Prevention of Experimental Invasive Pulmonary Aspergillosis: Correlation with Galactomannan Antigenemia. Antimicrob. Agents Chemother. 45: 857-869 [Abstract] [Full Text]  
  • Manavathu, E. K., Cutright, J. L., Loebenberg, D., Chandrasekar, P. H. (2000). A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46: 229-234 [Abstract] [Full Text]  
  • Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr., Moss, E. L. Jr., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G. H., Hare, R. S. (2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrob. Agents Chemother. 44: 2017-2022 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Molina, J., Martins-Filho, O., Brener, Z., Romanha, A. J., Loebenberg, D., Urbina, J. A. (2000). Activities of the Triazole Derivative SCH 56592 (Posaconazole) against Drug-Resistant Strains of the Protozoan Parasite Trypanosoma (Schizotrypanum) cruzi in Immunocompetent and Immunosuppressed Murine Hosts. Antimicrob. Agents Chemother. 44: 150-155 [Abstract] [Full Text]  
  • Barchiesi, F., Arzeni, D., Fothergill, A. W., Di Francesco, L. F., Caselli, F., Rinaldi, M. G., Scalise, G. (2000). In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens. Antimicrob. Agents Chemother. 44: 226-229 [Abstract] [Full Text]  
  • Hossain, M. A., Maesaki, S., Mitsutake, K., Kakeya, H., Sasaki, E., Tomono, K., Tashiro, T., Kohno, S. (1999). In-vitro and in-vivo activities of SCH56592 against Cryptococcus neoformans. J Antimicrob Chemother 44: 827-829 [Abstract] [Full Text]  
  • Lozano-Chiu, M., Arikan, S., Paetznick, V. L., Anaissie, E. J., Loebenberg, D., Rex, J. H. (1999). Treatment of Murine Fusariosis with SCH 56592. Antimicrob. Agents Chemother. 43: 589-591 [Abstract] [Full Text]  
  • Sheehan, D. J., Hitchcock, C. A., Sibley, C. M. (1999). Current and Emerging Azole Antifungal Agents. Clin. Microbiol. Rev. 12: 40-79 [Abstract] [Full Text]  
  • Fidel, P. L. Jr., Vazquez, J. A., Sobel, J. D. (1999). Candida glabrata: Review of Epidemiology, Pathogenesis, and Clinical Disease with Comparison to C. albicans. Clin. Microbiol. Rev. 12: 80-96 [Abstract] [Full Text]  
  • Espinel-Ingroff, A. (1998). Comparison of In Vitro Activities of the New Triazole SCH56592 and the Echinocandins MK-0991 (L-743,872) and LY303366 against Opportunistic Filamentous and Dimorphic Fungi and Yeasts. J. Clin. Microbiol. 36: 2950-2956 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»